Effects of Body-Mass-Scaled Protein and Leucine Supplementation on Body Composition and Cardiometabolic Blood Markers During Weight Loss in Older Men-A Randomized Controlled Trial.

Background

Overweight and obesity are burgeoning health epidemics. Diets including alternate-day fasting (ADF) promote weight loss but risk significant muscle loss, posing health implications to seniors at risk of sarcopenia. Leucine, the key muscle protein synthesis (MPS) driver, effectively stimulates MPS with lower calorie intake than protein. However, the effects of body-mass-scaled protein and leucine intakes are unclear.

Objectives

To evaluate body-mass-scaled leucine or protein supplementation on body composition, sarcopenic, and cardiometabolic markers in older men during ADF.

Methods

Sixty-one older men (BMI ≥ 23.0 kg/m2) underwent 28 days of ADF, randomized across three calorie-matched supplement groups: Control (C: 0.0 g/kg protein, 0.0 g/kg leucine), Leucine (L: 0.0 g/kg protein, 0.08 g/kg leucine), or Protein (P: 0.4 g/kg protein, 0.04 g/kg leucine), consuming three doses on feeding days and one on fasting days. Dual-energy X-ray absorptiometry, sarcopenic metrics, and blood markers (blood pressure, lipid panels, diabetic profiles) were measured.

Results

There were no significant interactions (p > 0.05) in body composition, sarcopenic or health outcomes, except for diastolic blood pressure (p = 0.016) and HDL cholesterol (p = 0.013). There were significant main effects of time (p ≤ 0.05) with reductions in all body composition measures (excluding bone mineral density, p = 0.274), systolic blood pressure and lipid profiles (total and LDL cholesterol, total/HDL cholesterol ratio, triglycerides), and improvements in all muscle strength and functional sarcopenic outcomes.

Conclusions

Dietary interventions alone that increase leucine and/or protein intake did not result in additional measurable improvements during this four-week intervention on body composition, sarcopenic, and cardiometabolic outcomes during weight loss.